HSTO

Histogen Inc. [HSTO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

HSTO Stock Summary

In the News

06:00 29 Mar 2024 HSTO

Top Sectors to Explore for Penny Stocks to Buy

Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:00 29 Mar 2024 HSTO

Penny Stock Psychology: Developing a Winning Mindset

Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

08:37 29 Mar 2024 HSTO

Why Is Histogen (HSTO) Stock Up 37% Today?

Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.

01:32 29 Mar 2024 HSTO

Histogen (HSTO) Upgraded to Strong Buy: Here's What You Should Know

Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10:08 29 Mar 2024 HSTO

Buying Biotech Penny Stocks? 3 Things to Look For

Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

04:05 29 Mar 2024 HSTO

Histogen to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen's Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

04:05 29 Mar 2024 HSTO

Histogen to Report First Quarter 2022 Financial Results and Provide Business Update

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.

01:45 29 Mar 2024 HSTO

5 Top Biotech Penny Stocks Under $1 To Watch This Week

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

03:02 29 Mar 2024 HSTO

Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

04:15 29 Mar 2024 HSTO

Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022.

HSTO Financial details

Company Rating
Neutral
Market Cap
1.39M
Income
-12.41M
Revenue
19K
Book val./share
1.27
Cash/share
1.07
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.12
Forward P/E
-
PEG
0.02
P/S
76.44
P/B
0.27
P/C
0.34
P/FCF
-0.14
Quick Ratio
3.39
Current Ratio
4.05
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.13
EPS next Y
-
EPS next Q
1.58
EPS this Y
-56.59%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-11.28%
Revenue last 5Y
-35.43%
Revenue Q/Q
-
EPS Q/Q
83.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
154.15%
Inst Trans
0.36%
ROA
-213%
ROE
-123%
ROC
-2.7%
Gross Margin
100%
Oper. Margin
-63447%
Profit Margin
-65295%
Payout
-
Shs Outstand
4.27M
Shs Float
3.93M
-
-
-
-
Target Price
-
52W Range
0.28-1.3
52W High
-
52W Low
-
RSI
52
Rel Volume
0.22
Avg Volume
23.74K
Volume
5.16K
Perf Week
-9.98%
Perf Month
7.49%
Perf Quarter
-50.06%
Perf Half Y
-31.29%
-
-
-
-
Beta
1.137
-
-
Volatility
0.03%, 0.03%
Prev Close
0%
Price
0.3601
Change
0%

HSTO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
11.0619.144.570.481.17
Net income per share
-5.93-8.29-57.16-7.51-3.26
Operating cash flow per share
-11.48-2.19-26.73-7.58-3.02
Free cash flow per share
-11.5-2.44-26.84-7.7-3.08
Cash per share
13.43.5159.743.77
Book value per share
9.02-62.7617.4311.054.49
Tangible book value per share
9.02-64.2815.3310.524.17
Share holders equity per share
9.02-62.7617.4311.054.49
Interest debt per share
0.210.2511.612.481.44
Market cap
1.05B47.26M6.85M12.66M2.67M
Enterprise value
1.04B45.34M5.39M-1.28M-4.82M
P/E ratio
-58.35-9.65-0.27-0.88-0.25
Price to sales ratio
31.294.183.3313.780.71
POCF ratio
-30.15-36.6-0.57-0.87-0.28
PFCF ratio
-30.09-32.75-0.57-0.86-0.27
P/B Ratio
38.35-1.270.870.60.19
PTB ratio
38.35-1.270.870.60.19
EV to sales
30.944.012.62-1.39-1.28
Enterprise value over EBITDA
-60.3443.18-1.180.080.45
EV to operating cash flow
-29.81-35.12-0.450.090.5
EV to free cash flow
-29.76-31.42-0.450.090.49
Earnings yield
-0.02-0.1-3.76-1.14-3.93
Free cash flow yield
-0.03-0.03-1.77-1.17-3.71
Debt to equity
000.670.220.32
Debt to assets
00.050.350.170.24
Net debt to EBITDA
0.67-1.830.320.90.7
Current ratio
2.561.783.029.2710.9
Interest coverage
-26.260183.03-1.55K-10.64K
Income quality
1.940.430.640.970.91
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.310.553.28.482.49
Research and developement to revenue
1.230.363.029.221.33
Intangibles to total assets
00000
Capex to operating cash flow
00.1200.020.02
Capex to revenue
0-0.01-0.02-0.26-0.06
Capex to depreciation
-0.73-1.05-0.5-2.48-1.54
Stock based compensation to revenue
0.110.040.30.770.13
Graham number
34.7108.2149.7343.2118.15
ROIC
-0.7-0.04-0.89-0.48-0.44
Return on tangible assets
-0.37-1.66-1.72-0.53-0.55
Graham Net
7.26-65.53-2.396.582.08
Working capital
28.91M1.08M5.62M19.28M12.22M
Tangible asset value
27.4M-37.97M6.91M20.19M13.38M
Net current asset value
26.02M-38.45M300K14.55M7.76M
Invested capital
000.670.220.32
Average receivables
3.52M1.89M127K154.5K132K
Average payables
0404K673.5K966K887.5K
Average inventory
053K203K1.01M1.06M
Days sales outstanding
39.963.5525.5365.539.59
Days payables outstanding
0133.15203.242.31K0
Days of inventory on hand
017.47113.122.87K0
Receivables turnover
9.13102.7614.35.5738.07
Payables turnover
02.741.80.160
Inventory turnover
020.93.230.130
ROE
-0.660.13-3.28-0.68-0.73
Capex per share
-0.02-0.26-0.11-0.13-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.01-0.93-0.81-0.49-0.9
Operating cash flow per share
-0.69-0.76-0.6-0.56-0.63
Free cash flow per share
-0.69-0.76-0.6-0.56-0.63
Cash per share
4.093.772.261.71.07
Book value per share
4.864.492.662.181.27
Tangible book value per share
4.574.172.421.931.03
Share holders equity per share
4.864.492.662.181.27
Interest debt per share
1.321.441.071.060
Market cap
4.8M2.67M5.17M3.03M2.2M
Enterprise value
-5.07M-4.81M85.83K287.95K-2.37M
P/E ratio
-0.33-0.22-0.37-0.36-0.14
Price to sales ratio
959.75666.311.03K606.59439.65
POCF ratio
-1.96-1.09-2.03-1.27-0.82
PFCF ratio
-1.95-1.09-2.03-1.27-0.82
P/B Ratio
0.280.190.460.330.4
PTB ratio
0.280.190.460.330.4
EV to sales
-1.01K-1.2K17.1757.59-474.95
Enterprise value over EBITDA
1.421.64-0.02-0.140.67
EV to operating cash flow
2.071.97-0.03-0.120.88
EV to free cash flow
2.061.97-0.03-0.120.88
Earnings yield
-0.75-1.12-0.67-0.69-1.75
Free cash flow yield
-0.51-0.92-0.49-0.79-1.22
Debt to equity
0.270.320.40.490
Debt to assets
0.210.240.290.330
Net debt to EBITDA
2.772.551.481.341.3
Current ratio
11.6910.97.928.544.05
Interest coverage
-3.6K2.97K3.47K-2.09K0
Income quality
0.680.820.731.150.7
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
539.2470.75497.2311.4574
Research and developement to revenue
181.4272.25198.6107.2132
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
-1.8-0.25000
Capex to depreciation
-0.24-0.03000
Stock based compensation to revenue
26.622.2583.86.4-1.4
Graham number
10.529.696.974.95.08
ROIC
-0.13-0.13-0.17-0.11-0.64
Return on tangible assets
-0.16-0.16-0.22-0.15-0.66
Graham Net
2.522.090.970.460.74
Working capital
14.94M12.22M9.27M7.31M4.11M
Tangible asset value
16.25M13.38M10.32M8.27M4.4M
Net current asset value
10.41M7.76M4.88M3M4.04M
Invested capital
0.270.320.40.490
Average receivables
199.5K86.5K61K11.5K0
Average payables
547.5K471.5K411.5K417.5K390K
Average inventory
617.5K535.5K432.5K192K0
Days sales outstanding
1.33K2.23K41400
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.070.040.2200
Payables turnover
00000
Inventory turnover
00000
ROE
-0.21-0.21-0.31-0.23-0.71
Capex per share
00000

HSTO Frequently Asked Questions

What is Histogen Inc. stock symbol ?

Histogen Inc. is a US stock , located in San diego of Ca and trading under the symbol HSTO

What is Histogen Inc. stock quote today ?

Histogen Inc. stock price is $0.3601 today.

Is Histogen Inc. stock public?

Yes, Histogen Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Price Range
Similar Market Cap